Rivaroxaban: An oral direct inhibitor of factor Xa
- 15 August 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (16), 1520-1529
- https://doi.org/10.2146/ajhp070624
Abstract
Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban are reviewed.Keywords
This publication has 39 references indexed in Scilit:
- RIVAROXABAN - AN ORAL, DIRECT FACTOR XA INHIBITOR - BINDS RAPIDLY TO FACTOR XAJournal of Thrombosis and Haemostasis, 2007
- Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic DiseasesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized TrialJAMA, 2006
- Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgeryBritish Journal of Surgery, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous ThrombosisAnnals of Internal Medicine, 2004
- Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary EmbolismNew England Journal of Medicine, 2003
- Formation of trisomies and their parental origin in hyperdiploid childhood acute lymphoblastic leukemiaBlood, 2003